National Bank of Canada’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
Other funds holding RXRX
MCMU
IEFM
LIM
National Bank of Canada's RXRX Position: Q2 2026 in Review
National Bank of Canada increased its Recursion Pharmaceuticals (RXRX) stake by 40,163% in Q2 2026, buying an estimated $2.46M and bringing the position to 739,631 shares worth $2.71M. The position accounts for ﹤0.01% of the portfolio, ranked #1062.
National Bank of Canada first reported a position in RXRX in Q2 2022 and has held it in 15 quarters since. The position peaked at $3.58M in Q4 2025. 218 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.
- National Bank of Canada held 739,631 shares of Recursion Pharmaceuticals worth $2.71M as of Q2 2026.
- National Bank of Canada bought 737,794 Recursion Pharmaceuticals shares in Q2 2026, an estimated $2.46M.
- Recursion Pharmaceuticals made up ﹤0.01% of National Bank of Canada's portfolio in Q2 2026, its #1062 holding.
- National Bank of Canada first reported a position in Recursion Pharmaceuticals in Q2 2022 and has held it in 15 quarters since.
- National Bank of Canada's Recursion Pharmaceuticals position peaked at $3.58M in Q4 2025.
- 218 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.
Based on National Bank of Canada's 13F filing for Q2 2026, filed 10 Aug 2026.